AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06311981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
Study NCT06311981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: targeted therapy
Study NCT06311981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single regimen chemotherapy in sequence with radiotherapy
Description: single regimen chemotherapy in sequence with radiotherapy
Study NCT04988620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
Study NCT04988620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
Study NCT05081206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion via manually controlled pump.
Description: Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
Study NCT05081206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion via target controlled pump.
Description: Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRA023 IV Low Dose
Description: Drug
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023 SC
Description: Drug
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo SC
Description: Placebo
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo
Study NCT05354349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023 IV High Dose
Description: Drug
Study NCT05287165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM96 CAR-T cells
Description: treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
Study NCT05554666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG315
Description: Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
Study NCT06075433 — intervention group
Intervention type: DEVICE
Intervention: Genoss DES stent
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study NCT05943379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC in Combination with gemcitabine
Description: RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
Study NCT04768621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionary
Description: Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
Study NCT04768621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionary
Description: Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
Study NCT04957628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Harmful alcohol use treatment
Description: Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C > 6 (men) / > 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
Study NCT04957628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Non-prescribed psychoactive medicinal use treatment
Description: Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
Study NCT05110300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight support system control group
Description: Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
Study NCT05110300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body weight support system with balance perturbations
Description: Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
Study NCT05931601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: See arm description
Study NCT05509426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
Study NCT05230472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 60 mg tab
Study NCT06344299 — intervention group
Intervention type: OTHER
Intervention: potential predictors
Description: Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
Study NCT06110208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLL1 and CD38 dual-target CAR-T injection
Description: CLL1 and CD38 dual-target CAR-T injection
Study NCT05786508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partners4Pain program
Description: Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks
Study NCT05786508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Key to Wellbeing program
Description: Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks
Study NCT04890470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin (24 IU)
Study NCT04890470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: intranasal administration of vasopressin (20 IU)
Study NCT04890470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study NCT05753059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
Study NCT05753059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
Study NCT05753059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Study NCT05753059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendroflumethiazide
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Study NCT06130722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL115
Description: FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
Study NCT05104242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in Advanced Glycation End-Products (AGE)
Description: The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Dose will be assigned at study entry. Give IV over 15 minutes.
Study NCT05575089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training - Powerbreath
Description: The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training.
Study NCT05575089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise in cycle ergometer
Description: 10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
Study NCT05575089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in cycle ergometer
Description: 10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
Study NCT05575089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep breathing exercises
Description: Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
Study NCT05575089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Description: Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
Study NCT04859426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral
Study NCT05733156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + LDRT
Description: Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
Study NCT05023993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Complete home exercise
Study NCT05023993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home exercise
Study NCT05023993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Given PO
Study NCT04602117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Description: SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly.
Study NCT05195658 — intervention group
Intervention type: DEVICE
Intervention: Thrombectomy and Stenting under neuroprotection
Description: Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center.
Study NCT05039970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WellQuest™
Description: WellQuest™ is a mobile device-based serious health game.
Study NCT05355844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Description: Benzoyl peroxide application in the incision area before surgery
Study NCT05355844 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Benzoyl peroxide
Description: Benzoyl peroxide application in the incision area before surgery
Study NCT04866602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atoguanil
Description: Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
Study NCT04866602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~* Any oral formulation of dexamethasone is acceptable.~* IV may be given if oral formulation is not tolerated
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: * 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~* Infusion will start 30 minutes after start of tagraxofusp on day 8.
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: * 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine IT
Description: Give intrathecally:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Study NCT05476770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Study NCT04920838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide and Ciclésonide
Description: Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
Study NCT04920838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20Mg Oral Tablet
Description: 20 mg tablet daily
Study NCT04920838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days
Study NCT04920838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxétine and Budésonide
Description: Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
Study NCT06448611 — intervention group
Intervention type: OTHER
Intervention: Blood Test
Description: Research and quantification of Circulating Tumor Cells
Study NCT05292716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: MitraClip
Study NCT06143267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of either NST or placebo at different blood glucose levels
Description: In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.